| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
34,935 |
21,580 |
$1.37M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
22,374 |
13,977 |
$1.32M |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
6,883 |
4,739 |
$460K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
6,112 |
3,768 |
$402K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
5,753 |
3,687 |
$378K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
13,298 |
7,740 |
$336K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
3,171 |
1,817 |
$191K |
| 99442 |
|
6,294 |
3,794 |
$128K |
| 99490 |
Ccm add 20min |
5,287 |
3,774 |
$119K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
17,944 |
11,175 |
$110K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
10,046 |
6,176 |
$35K |
| 97802 |
|
14,748 |
9,588 |
$34K |
| 99401 |
|
2,031 |
1,518 |
$28K |
| 90461 |
|
5,267 |
2,509 |
$21K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,004 |
1,803 |
$18K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
22,499 |
13,311 |
$17K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
6,456 |
3,848 |
$13K |
| 99215 |
Prolong outpt/office vis |
97 |
87 |
$13K |
| 94664 |
|
1,702 |
1,320 |
$10K |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
5,600 |
3,797 |
$9K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
304 |
132 |
$9K |
| 69210 |
|
680 |
474 |
$9K |
| 87807 |
|
1,236 |
747 |
$8K |
| 99491 |
Ccm add 20min |
286 |
166 |
$8K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
775 |
407 |
$7K |
| 96127 |
|
4,464 |
1,907 |
$6K |
| 99443 |
|
64 |
62 |
$6K |
| 99243 |
|
159 |
63 |
$3K |
| 90686 |
|
6,214 |
4,540 |
$3K |
| 99050 |
|
2,472 |
1,799 |
$3K |
| 94667 |
|
498 |
472 |
$3K |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
5,707 |
3,147 |
$2K |
| 99188 |
|
822 |
547 |
$2K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
65 |
40 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
136 |
100 |
$2K |
| A7015 |
Aerosol mask, used with dme nebulizer |
5,595 |
3,057 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
442 |
157 |
$789.78 |
| 90651 |
|
2,503 |
1,521 |
$488.07 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
2,313 |
1,182 |
$475.66 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
14 |
14 |
$345.66 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
36 |
29 |
$311.09 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
13 |
13 |
$291.58 |
| 99058 |
|
20,535 |
12,280 |
$279.18 |
| Q3014 |
Telehealth originating site facility fee |
5,142 |
2,486 |
$277.55 |
| S9451 |
Exercise classes, non-physician provider, per session |
17,875 |
11,279 |
$266.85 |
| 0001A |
|
42 |
12 |
$249.96 |
| S0302 |
Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) |
437 |
429 |
$223.40 |
| 90670 |
|
2,639 |
1,422 |
$204.06 |
| 90680 |
|
1,166 |
540 |
$199.08 |
| 90734 |
|
709 |
610 |
$178.02 |
| 99421 |
|
19 |
15 |
$165.00 |
| 90698 |
|
1,422 |
635 |
$159.54 |
| 99406 |
|
30 |
30 |
$147.24 |
| 90633 |
|
1,469 |
810 |
$132.03 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,194 |
357 |
$102.07 |
| 99173 |
|
13,747 |
7,251 |
$78.76 |
| 96160 |
|
3,083 |
2,381 |
$74.49 |
| 90700 |
|
241 |
190 |
$68.01 |
| 99174 |
|
3,222 |
3,102 |
$53.02 |
| 90685 |
|
123 |
118 |
$34.01 |
| 90744 |
|
478 |
200 |
$34.01 |
| 94761 |
|
1,041 |
922 |
$4.26 |
| 90707 |
|
134 |
129 |
$0.00 |
| 90672 |
|
146 |
146 |
$0.00 |
| 90710 |
|
184 |
123 |
$0.00 |
| S9441 |
Asthma education, non-physician provider, per session |
271 |
221 |
$0.00 |
| 90715 |
|
575 |
261 |
$0.00 |
| 91300 |
|
94 |
30 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
45 |
38 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
26 |
24 |
$0.00 |
| 90648 |
|
24 |
24 |
$0.00 |
| G9920 |
Screening performed and negative |
67 |
67 |
$0.00 |
| 81002 |
|
24 |
24 |
$0.00 |
| 90713 |
|
17 |
17 |
$0.00 |
| 90621 |
|
13 |
13 |
$0.00 |
| 90620 |
|
469 |
234 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,347 |
996 |
$0.00 |
| 90716 |
|
89 |
84 |
$0.00 |
| 90696 |
|
60 |
26 |
$0.00 |
| 90697 |
|
12 |
12 |
$0.00 |
| 90619 |
|
430 |
108 |
$0.00 |
| 90677 |
|
14 |
14 |
$0.00 |